Benitec will present interim clinical results from the ongoing BB-301 Phase 1b/2a study as a late-breaking poster presentation, which will encompass 12-month follow-up data for all six Cohort 1 ...
A sweeping new review argues that RNA interference could become a cornerstone of sustainable crop protection, but variable ...
A brief history of Arbutus Biopharma◾️A company that began with RNA medicine technologyTechnical roots from Inex to TekmiraTo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results